PTC Therapeutics Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. I...
Latest News
3 days ago · seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call TranscriptPTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
3 days ago · zacks.com
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
3 days ago · zacks.com
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass EstimatesPTC Therapeutics (PTCT) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.2 per share a year ago.
11 days ago · zacks.com
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out forPTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 months ago · seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptPTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
3 months ago · seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study TranscriptPTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript
3 months ago · zacks.com
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerPTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
3 months ago · zacks.com
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesAlthough the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
3 months ago · seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call TranscriptPTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
3 months ago · zacks.com
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue EstimatesPTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PTCT